For the quarter ending 2025-09-30, CATX made $209,000 in revenue. -$25,969,000 in net income. Net profit margin of -12425.36%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Grant revenue | 209,000 | 290,000 | 342,000 | 361,666.667 |
| Research and development | 20,339,000 | 16,620,000 | 14,332,000 | 9,870,000 |
| Goodwill, impairment loss | - | - | - | 6,015,500 |
| General and administrative | 7,731,000 | 7,709,000 | 7,842,000 | 6,546,000 |
| Loss on disposal of property and equipment | - | - | - | 2,000,666.667 |
| Total operating expenses | 28,070,000 | 24,329,000 | 22,174,000 | 24,445,666.667 |
| Operating loss | -27,861,000 | -24,039,000 | -21,832,000 | -24,084,000 |
| Interest income | 1,957,000 | 2,159,000 | 2,384,000 | 2,311,333.333 |
| Interest and other expense | 65,000 | 119,000 | 128,000 | - |
| Other income from a related party (note 3) | 0 | 0 | 1,400,000 | - |
| Equity in loss of affiliate | 0 | 0 | -1,000 | -2,000 |
| Interest and other expense, net | - | - | - | 12,000 |
| Total non-operating income, net | 1,892,000 | 2,040,000 | 3,655,000 | 2,315,666.667 |
| Net loss from continuing operations | -25,969,000 | -21,999,000 | -18,177,000 | -21,768,333.333 |
| Net loss before deferred income tax benefit | - | - | - | -22,084,666.667 |
| Deferred income tax benefit | - | - | - | -524,250 |
| Net gain (loss) from discontinued operations | 0 | 514,000 | - | -237,250 |
| Net loss | -25,969,000 | -21,485,000 | -18,177,000 | -21,385,666.667 |
| Basic and diluted (in shares) | 74,296,000 | 74,235,000 | 72,357,000 | -2,068,000 |
| Basic loss per share | -0.35 | -0.29 | -0.25 | -0.34 |
| Diluted loss per share | -0.35 | -0.29 | -0.25 | -0.34 |
| Weighted average number of shares outstanding, diluted, total | 74,296,000 | 74,235,000 | 72,357,000 | -2,068,000 |
Perspective Therapeutics, Inc. (CATX)
Perspective Therapeutics, Inc. (CATX)